Pneumococcal conjugate 26 valent vaccine - Beijing Zhifei Lvzhu Biopharmaceutical
Alternative Names: 26-valent Pneumococcal Conjugate Vaccine -Beijing Zhifei Lvzhu Biopharmaceutical; PCV-26Latest Information Update: 19 May 2025
At a glance
- Originator Beijing Zhifei Lvzhu Biopharmaceutical
- Class Conjugate vaccines; Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Pneumococcal infections
Most Recent Events
- 18 May 2025 Beijing Zhifei Lvzhu Biopharmaceutical plans a phase I trial for Pneumococcal infections (Prevention) in the Australia (IM, Injection)in May 2025 (NCT06970756)
- 27 Aug 2024 Phase-I/II clinical trials in Pneumococcal infections (Prevention, In adolescents, In adults, In children, In infants) in China (IM), (NCT06703203),
- 01 Apr 2024 Beijing Zhifei Lvzhu Biopharmaceutical files an clinical trial application for Pneumococcal infections (Prevention) prior to April 2024